Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. GPCR
stocks logo

GPCR

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
--
--
-0.370
+105.56%
--
--
-0.395
+97.5%
--
--
-0.064
-71.02%
Estimates Revision
The market is revising No Change the revenue expectations for Structure Therapeutics Inc. (GPCR) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 33.29%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+3.09%
In Past 3 Month
Stock Price
Go Up
up Image
+33.29%
In Past 3 Month
12 Analyst Rating
up Image0
Wall Street analysts forecast GPCR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GPCR is 78.73 USD with a low forecast of 50.00 USD and a high forecast of 120.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Buy
0 Hold
0 Sell
Strong Buy
up Image0
Current: 18.860
sliders
Low
50.00
Averages
78.73
High
120.00
up Image0
Current: 18.860
sliders
Low
50.00
Averages
78.73
High
120.00
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$75 -> $80
2025-05-12
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$75 -> $80
2025-05-12
maintain
Buy
Reason
HC Wainwright & Co.
Andrew Fein
Strong Buy
Maintains
$80
2025-04-22
Reason
HC Wainwright & Co.
Andrew Fein
Price Target
$80
2025-04-22
Maintains
Strong Buy
Reason
William Blair
Andy Hsieh
Buy
Initiates
n/a
2025-02-28
Reason
William Blair
Andy Hsieh
Price Target
n/a
2025-02-28
Initiates
Buy
Reason
Citizens Capital Markets
Jonathan Wolleben
Buy
Maintains
$91 → $87
2025-02-28
Reason
Citizens Capital Markets
Jonathan Wolleben
Price Target
$91 → $87
2025-02-28
Maintains
Buy
Reason
Stifel
Annabel Samimy
Strong Buy
Initiates
$50
2025-01-08
Reason
Stifel
Annabel Samimy
Price Target
$50
2025-01-08
Initiates
Strong Buy
Reason
HC Wainwright & Co.
Andrew Fein
Strong Buy
Reiterates
$80
2024-12-20
Reason
HC Wainwright & Co.
Andrew Fein
Price Target
$80
2024-12-20
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Structure Therapeutics Inc (GPCR.O) is -17.06, compared to its 5-year average forward P/E of -37.35. For a more detailed relative valuation and DCF analysis to assess Structure Therapeutics Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-37.35
Current PE
-17.06
Overvalued PE
-24.66
Undervalued PE
-50.04

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-4.07
Current EV/EBITDA
-1.40
Overvalued EV/EBITDA
0.21
Undervalued EV/EBITDA
-8.34

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.71
Current PS
23.43
Overvalued PS
12.90
Undervalued PS
-5.49

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

GPCR News & Events

Events Timeline

(ET)
2025-04-17
10:20:09
JPMorgan says Lilly data 'highly favorable' for Structure Therapeutics
select
2025-04-14 (ET)
2025-04-14
09:53:27
JPMorgan says Pfizer news 'mostly a positive' for Structure, Viking
select
2025-04-14
09:47:15
Viking, Structure rally after Pfizer halts obesity drug development
select
Sign Up For More Events
Sign Up For More Events

News

Preview
4.0
06-23Benzinga
Cantor Fitzgerald Reiterates Overweight on Structure Therapeutics, Maintains $65 Price Target

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, providing real-time intelligence to help them succeed in the stock market.

  • Community and Exclusivity: Joining Benzinga Pro connects users with over 10,000 serious traders and grants access to exclusive stories and insights from Benzinga reporters.

Preview
9.0
06-21NASDAQ.COM
Structure Therapeutics Inc. Announces Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions

  • Upcoming Presentations: Structure Therapeutics Inc. will present data on ACCG-2671, an oral treatment for obesity, and GSBR-5595, a GLP-1 receptor agonist for Parkinson's disease, at the American Diabetes Association 85th Scientific Sessions on June 22, 2025.

  • Therapeutic Potential: Preclinical results indicate that ACCG-2671 significantly reduces body weight when used alone or with a GLP-1 receptor agonist, while GSBR-5595 shows promise in improving motor coordination and neuroprotection in Parkinson's disease models.

Preview
9.0
06-21Newsfilter
Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

  • Upcoming Presentations: Structure Therapeutics Inc. will present two late-breaking posters at the American Diabetes Association's 85th Scientific Sessions, showcasing their oral small molecule ACCG-2671 for obesity therapy and a GLP-1 receptor agonist's effects in Parkinson's disease models.

  • Research Findings: Preclinical data indicates that ACCG-2671 significantly reduces body weight in obese rats and shows potential as a treatment backbone, while another compound demonstrated neuroprotective effects in Parkinson's disease by improving motor coordination and preserving dopaminergic neurons.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Structure Therapeutics Inc (GPCR) stock price today?

The current price of GPCR is 18.86 USD — it has increased 0.69 % in the last trading day.

arrow icon

What is Structure Therapeutics Inc (GPCR)'s business?

Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.

arrow icon

What is the price predicton of GPCR Stock?

Wall Street analysts forecast GPCR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GPCR is 78.73 USD with a low forecast of 50.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Structure Therapeutics Inc (GPCR)'s revenue for the last quarter?

Structure Therapeutics Inc revenue for the last quarter amounts to -56.31M USD, increased 75.89 % YoY.

arrow icon

What is Structure Therapeutics Inc (GPCR)'s earnings per share (EPS) for the last quarter?

Structure Therapeutics Inc. EPS for the last quarter amounts to -52543000.00 USD, increased 53.45 % YoY.

arrow icon

What changes have occurred in the market's expectations for Structure Therapeutics Inc (GPCR)'s fundamentals?

The market is revising No Change the revenue expectations for Structure Therapeutics Inc. (GPCR) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 33.29%.
arrow icon

How many employees does Structure Therapeutics Inc (GPCR). have?

Structure Therapeutics Inc (GPCR) has 163 emplpoyees as of July 08 2025.

arrow icon

What is Structure Therapeutics Inc (GPCR) market cap?

Today GPCR has the market capitalization of 1.08B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free